A neuroscience target for an undisclosed neurodegenerative disease marks the first validated output from a partnership worth up to $12 billionAfter nearly five years of collaboration, Roche and Recursion Pharmaceuticals have something concrete to show for it. On August 5, 2026, the two companies confirmed that their first AI-identified drug target had been advanced, a neuroscience candidate aimed at treating an undisclosed neurodegenerative disease. Recursion CEO Najat Khan pointed to the company’s AI platform, called Recursion OS, as the engine behind the discovery. For this neuroscience target specifically, the analysis drew on whole-genome CRISPR knockout data from neuronal cells. The neuroscience result, she said, illustrates that the platform can surface targets that conventional methods have missed.